Last reviewed · How we verify

Lidocaine 5% patch — Competitive Intelligence Brief

Lidocaine 5% patch (Lidocaine 5% patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Pain management / Dermatology.

marketed Local anesthetic Voltage-gated sodium channels Pain management / Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Lidocaine 5% patch (Lidocaine 5% patch) — Beijing Tiantan Hospital. Lidocaine blocks sodium channels in nerve fibers, preventing the initiation and conduction of nerve impulses to produce local anesthesia.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lidocaine 5% patch TARGET Lidocaine 5% patch Beijing Tiantan Hospital marketed Local anesthetic Voltage-gated sodium channels
Propofol/Lidocaine Propofol/Lidocaine NYU Langone Health marketed Intravenous anesthetic combination GABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
Dexamethasone+ Bupivacaine Dexamethasone+ Bupivacaine Ain Shams University marketed Corticosteroid + Local anesthetic combination Glucocorticoid receptor (dexamethasone); Voltage-gated sodium channels (bupivacaine)
Bupivacaine (Marcaine) Bupivacaine (Marcaine) NYU Langone Health marketed Local anesthetic (amide) Voltage-gated sodium channels
Control (bupivacaine) Control (bupivacaine) Kasr El Aini Hospital marketed Local anesthetic (amide) Voltage-gated sodium channels
Suzetrigine (SUZ) Suzetrigine (SUZ) Vertex Pharmaceuticals Incorporated marketed Selective sodium channel inhibitor Voltage-gated sodium channels (Nav)
lamotrigine (generic Teva) lamotrigine (generic Teva) University of Maryland, Baltimore marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

  1. University of California, San Diego · 3 drugs in this class
  2. Durect · 3 drugs in this class
  3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
  4. Wake Forest University Health Sciences · 3 drugs in this class
  5. Medical University of Vienna · 3 drugs in this class
  6. Imperial College London · 2 drugs in this class
  7. Hvidovre University Hospital · 2 drugs in this class
  8. Innocoll · 2 drugs in this class
  9. George Washington University · 2 drugs in this class
  10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lidocaine 5% patch — Competitive Intelligence Brief. https://druglandscape.com/ci/lidocaine-5-patch. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: